Human and Mouse Linked Evaluation of Tumors (HAMLET)
Supports all phases of human breast cancer research, discovery, validation, and treatment.
The mission of the Human and Mouse Linked Evaluation of Tumors (HAMLET) Core is to promote understanding of the biology and genetics of Human Breast Cancer, and to provide better preclinical models for the validation of new treatment and imaging approaches.
Read the full scientific focus of the HAMLET Core.
Each Washington University Human-in-Mouse (WHIM) line has been expanded and the material is distributed on a first-come, first-served basis; subject to availability. WHIM material available includes:
- Live frozen cells
- Live tumor bearing mice
- Protein lysates
- DNA and RNA
- Formalin fixed material
View more on specific data, and contact Shunqiang Li at email@example.com if you have questions.
The HAMLET core also provides:
- Therapeutic or imaging experiments in collaboration with academic investigators (the price list for these materials and services is available on demand)
- Patients’ clinical outcomes, therapeutic history and responsiveness to treatment
- Pre-publication data (available through project consultation work)
- Existing Genomic and Proteomic data (publicly available for each WHIM line once it has been published)
- Establishment of patient-derived xenograft models from other, non-breast, cancer types
The Human & Mouse Linked Evaluation of Tumors (HAMLET) Core occupies approximately 381 sq. ft. of space located in the Southwest Tower of Barnes-Jewish Hospital, and houses the following pieces of equipment:
- Dissecting microscope
- Fluorescence microscope
- Laminar flow hood
- Three Refrigerators
- -200C freezer
- Liquid nitrogen tank
A requirement for user publications is that the source of the material must be credited to the HAMLET Core and the relevant grants that generated the resource.
Email Shunqiang Li, PhD, at firstname.lastname@example.org to request information about services that are currently offered.
Service available to:
All entities, including for-profit organizations, with priority given to ICTS members.
For ICTS members, initial consultations are fully subsidized by the ICTS. Services above a consultation level are provided through charge-back and collaborations through percent effort. Contact core representatives to discuss service needs and any associated costs.
- Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft: Nature publication
- Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models: JCI publication
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts: Cell Reports publication
- Hamlet in the News: New models of drug-resistant breast cancer hint at better treatments
Shunqiang Li, PhD, Director